ClinicalTrials.Veeva

Find clinical trials for Lymphoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Barcelona, CT, ESP:

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Barcelona, Spain and 26 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Barcelona, Spain and 88 other locations

multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 16 other locations

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: HMPL-523

Phase 1

HUTCHMED
HUTCHMED

Barcelona, Spain and 31 other locations

1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...

Enrolling
Lymphoma
Solid Tumor, Adult
Drug: Fadraciclib

Phase 1, Phase 2

Cyclacel Pharmaceuticals

Barcelona, Spain and 3 other locations

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Barcelona, Spain and 50 other locations

TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess...

Enrolling
Mantle Cell Lymphoma (MCL)
Drug: Venetoclax
Drug: Rituximab

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 47 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Mosunetuzumab
Drug: Obinutuzumab

Phase 1

ADC Therapeutics

Barcelona, Spain and 26 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo

Barcelona, Spain and 59 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Barcelona, Spain and 95 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems